Twist Bioscience Corporation (TWST) Stock Grade

About Twist Bioscience Corporation's fundamentals

Twist Bioscience is a diagnostics and research company with a market capitalization of $1.7 billion that is experiencing solid revenue growth of 20.3% year-over-year. However, the company is currently unprofitable, with a net margin of -20.6%, and reported a net loss in its latest annual statement, indicating it is still in an investment phase. The company does not pay a dividend, which is typical for growth-stage biotech firms that reinvest cash into operations. Given the absence of profitability metrics, traditional valuation measures like P/E ratio and return on equity are not applicable at this time.